lomustine has been researched along with Benign Neoplasms in 46 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The paper reports on a trial in which nitrosomethylurea (NMU) was compared with CCNU both in combination with vincristine and dactinomycin or the same combination with DTIC in the treatment of disseminated skin melanoma." | 3.66 | Modern problems of clinical chemotherapy of malignant tumours. ( Bychkov, MB; Perevodchikova, NI, 1980) |
| "While maintaining a standard toceranib dosage [2." | 2.82 | Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study. ( Kurzman, ID; Pan, X; Tsimbas, K; Vail, DM, 2016) |
| " Hence, inhibitors of the TGF-β signaling pathway require a careful identification of a safe therapeutic window and a comprehensive monitoring of the cardiovascular system." | 2.80 | Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. ( Azaro, A; Baselga, J; Carducci, M; Cleverly, AL; Corretti, M; Dolan, M; Fernández, MS; Gueorguieva, I; Kovacs, RJ; Lahn, MM; Maldonado, G; Pillay, NS; Romero, FL; Sepulveda-Sánchez, JM, 2015) |
| " Design The first-in-human dose study had three parts (Part A, dose escalation, n = 39; Part B, safety combination with lomustine, n = 26; Part C, relative bioavailability study, n = 14)." | 2.80 | Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. ( Azaro, A; Baselga, J; Blakeley, J; Braña, I; Calvo, E; Carducci, M; Cleverly, A; Desaiah, D; Estrem, ST; Gueorguieva, I; Holdhoff, M; Lahn, MM; Paz-Ares, L; Pillay, NS; Rodón, J; Seoane, J; Sepulveda-Sánchez, JM; Sicart, E, 2015) |
| "Lomustine is a commercially available chloroethyl nitrosourea compound whose antitumor activity in vitro and in animal tumor models exceeds its activity in humans." | 2.67 | A phase I trial of weekly lomustine in patients with advanced cancer. ( Benjamin, RS; Gorski, CC; Koller, CA; Legha, SS; Papadopoulos, NE; Plager, C, 1994) |
| "Several anticancer drugs have been added to the therapeutic armamentarium in recent years." | 2.42 | New chemotherapy agents in veterinary medicine. ( Kitchell, BE; Moore, AS, 2003) |
| " Since no epidemiological data in man are available, extrapolation of animal data to man are important as well as dose-response studies in risk evaluations." | 2.37 | Carcinogenic N-nitroso compounds and their environmental significance. ( Preussmann, R, 1984) |
| " In order to enhance clinical effects of the nitrosoureas, further investigation of the design in therapeutic schedules on the basis of their pharmacokinetic characteristics will be needed." | 2.36 | [Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas]. ( Wakui, A, 1982) |
| " No association between dosing frequency, cumulative dose, initial starting dose or concurrent medications, and increases in ALT were found." | 1.38 | Low apparent risk of CCNU (lomustine)-associated clinical hepatotoxicity in cats. ( Chretin, JD; Musser, ML; Quinn, HT, 2012) |
| "Secondary tumors were noted in 8 out of 675 patients with Hodgkin's disease during remission following treatment." | 1.27 | [Secondary malignant tumors following treatment of Hodgkin's disease]. ( Shishkin, IP, 1984) |
| " The therapy is to be used effectfully only then, when indication, dosage and control of the patients are performed critically and exactly." | 1.26 | [Chemotherapy of malignant solid tumors]. ( Knöll, P; Siering, H, 1980) |
| " The treatment dosage was 130 mg/m2 for patients with adequate bone marrow reserve and 100 mg/m2 for those with compromised bone marrow." | 1.26 | Treatment of advanced malignancy with CCNU (NSC 79037): a phase II cooperative study with long-term follow up. ( Armstrong, DM; Aust, JB; Cruz, AB; Fletcher, WS; Metter, G; Richardson, JD; Wilson, WL, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (76.09) | 18.7374 |
| 1990's | 2 (4.35) | 18.2507 |
| 2000's | 2 (4.35) | 29.6817 |
| 2010's | 7 (15.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perjési, P | 1 |
| Das, U | 1 |
| De Clercq, E | 1 |
| Balzarini, J | 1 |
| Kawase, M | 1 |
| Sakagami, H | 1 |
| Stables, JP | 1 |
| Lorand, T | 1 |
| Rozmer, Z | 1 |
| Dimmock, JR | 1 |
| Taylor, JW | 1 |
| Armstrong, T | 1 |
| Kim, AH | 1 |
| Venere, M | 1 |
| Acquaye, A | 1 |
| Schrag, D | 1 |
| Wen, PY | 1 |
| Pan, X | 1 |
| Tsimbas, K | 1 |
| Kurzman, ID | 1 |
| Vail, DM | 1 |
| Kovacs, RJ | 1 |
| Maldonado, G | 1 |
| Azaro, A | 2 |
| Fernández, MS | 1 |
| Romero, FL | 1 |
| Sepulveda-Sánchez, JM | 2 |
| Corretti, M | 1 |
| Carducci, M | 2 |
| Dolan, M | 1 |
| Gueorguieva, I | 2 |
| Cleverly, AL | 1 |
| Pillay, NS | 2 |
| Baselga, J | 2 |
| Lahn, MM | 2 |
| Rodón, J | 1 |
| Calvo, E | 1 |
| Seoane, J | 1 |
| Braña, I | 1 |
| Sicart, E | 1 |
| Cleverly, A | 1 |
| Desaiah, D | 1 |
| Estrem, ST | 1 |
| Paz-Ares, L | 1 |
| Holdhoff, M | 1 |
| Blakeley, J | 1 |
| Buzás, K | 1 |
| Marton, A | 1 |
| Vizler, C | 1 |
| Gyukity-Sebestyén, E | 1 |
| Harmati, M | 1 |
| Nagy, K | 1 |
| Zvara, Á | 1 |
| Katona, RL | 1 |
| Tubak, V | 1 |
| Endrész, V | 1 |
| Németh, IB | 1 |
| Oláh, J | 1 |
| Vígh, L | 1 |
| Bíró, T | 1 |
| Kemény, L | 1 |
| Heading, KL | 1 |
| Brockley, LK | 1 |
| Bennett, PF | 1 |
| Musser, ML | 1 |
| Quinn, HT | 1 |
| Chretin, JD | 1 |
| Moore, AS | 1 |
| Kitchell, BE | 1 |
| Siering, H | 1 |
| Knöll, P | 1 |
| Wakui, A | 1 |
| Adams, GE | 1 |
| Perevodchikova, NI | 1 |
| Bychkov, MB | 1 |
| Preussmann, R | 1 |
| Siemann, DW | 1 |
| Fingert, HJ | 1 |
| Hochberg, FH | 1 |
| Tanneberger, S | 1 |
| Müller, U | 1 |
| Macdonald, JS | 1 |
| Hoth, D | 1 |
| Schein, PS | 1 |
| Roberts, JT | 1 |
| Bleehen, NM | 1 |
| Lee, FY | 1 |
| Workman, P | 1 |
| Walton, MI | 1 |
| Shishkin, IP | 1 |
| Weiss, RB | 1 |
| Issell, BF | 1 |
| Robak, T | 1 |
| Jones, AC | 1 |
| Stratford, IJ | 1 |
| Wilson, PA | 1 |
| Peckham, MJ | 1 |
| Gorin, NC | 2 |
| David, R | 2 |
| Stachowiak, J | 2 |
| Salmon, C | 2 |
| Petit, JC | 2 |
| Parlier, Y | 2 |
| Najman, A | 2 |
| Duhamel, G | 2 |
| Lambert, B | 1 |
| Bredberg, A | 1 |
| McKenzie, W | 1 |
| Sten, M | 1 |
| Castronovo, FP | 1 |
| Potsaid, MS | 1 |
| Kopiwoda, SY | 1 |
| Lind, MJ | 1 |
| Ardiet, C | 1 |
| Koller, CA | 1 |
| Gorski, CC | 1 |
| Benjamin, RS | 1 |
| Legha, SS | 1 |
| Papadopoulos, NE | 1 |
| Plager, C | 1 |
| Salem, PA | 1 |
| Hoogstraten, B | 1 |
| Haas, CD | 1 |
| Haut, A | 1 |
| Talley, RW | 1 |
| Rivkin, S | 1 |
| Isaacs, BL | 1 |
| Hirsch Marie, F | 1 |
| Muller, JY | 1 |
| Leblanc, G | 1 |
| Jullien, AM | 1 |
| Cavalier, J | 1 |
| Greenspan, EM | 1 |
| Domellöf, L | 1 |
| Athlin, L | 1 |
| Berghem, L | 1 |
| Goldin, A | 1 |
| Lokich, JJ | 1 |
| Skarin, AT | 1 |
| Hill, GJ | 1 |
| Johnson, RO | 1 |
| Metter, G | 2 |
| Wilson, WL | 2 |
| Davis, HL | 1 |
| Grage, T | 1 |
| Fletcher, WS | 2 |
| Golomb, FM | 1 |
| Cruz, AB | 2 |
| Armstrong, DM | 1 |
| Aust, JB | 1 |
| Richardson, JD | 1 |
| Slavik, M | 1 |
| Brooks, JC | 1 |
| Kaufman, J | 1 |
| Douglass, HO | 1 |
| Gerner, RE | 1 |
| Moore, GE | 1 |
| Dickey, C | 1 |
| Salmon, SE | 1 |
| Gerson, SL | 1 |
| Wang, QL | 1 |
| Vyas, RC | 1 |
| Adhvaryu, SG | 1 |
| Shah, VC | 1 |
| Mulcahy, RT | 1 |
| Baumgartner, G | 1 |
| Baumgartner, M | 1 |
7 reviews available for lomustine and Benign Neoplasms
| Article | Year |
|---|---|
New chemotherapy agents in veterinary medicine.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Deoxycytidine; Dog Diseases; Dogs; Gemcitabine; | 2003 |
[Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas].
Topics: Carmustine; Humans; Kinetics; Lomustine; Neoplasms; Nimustine; Nitrosourea Compounds; Semustine; Sol | 1982 |
Carcinogenic N-nitroso compounds and their environmental significance.
Topics: Alkylation; Animals; Brain Neoplasms; Carcinogens; Carcinogens, Environmental; Carmustine; Dimethyln | 1984 |
Modification of chemotherapy by nitroimidazoles.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; DNA Repair; Drug Synergism; Glutathione; Lomustine | 1984 |
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
Topics: Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hod | 1982 |
Pharmacokinetics of alkylating agents.
Topics: Alkylating Agents; Carmustine; Chlorambucil; Cyclophosphamide; Humans; Ifosfamide; Lomustine; Melpha | 1993 |
Advances in cancer chemotherapy.
Topics: Bleomycin; Burkitt Lymphoma; Carcinoma, Basal Cell; Choriocarcinoma; Cyclophosphamide; Cytarabine; D | 1975 |
7 trials available for lomustine and Benign Neoplasms
| Article | Year |
|---|---|
Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Combinati | 2016 |
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Pressure; Echocardiog | 2015 |
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Topics: ADAM Proteins; Adult; Aged; Anticonvulsants; Area Under Curve; Blood Cell Count; Chemokine CCL22; Do | 2015 |
[Use of nitrosourea compounds in cancer chemotherapy].
Topics: Carmustine; Clinical Trials as Topic; Humans; Lomustine; Neoplasms; Nitrosourea Compounds; Semustine | 1982 |
A phase I trial of weekly lomustine in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Capsules; Carcinoma, Renal Cell; Drug Administration Schedule; Dr | 1994 |
Nitrosourea combination chemotherapy: 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (methyl-CCNU) and cyclophosphamide.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Sched | 1975 |
Combination chemotherapy in disseminated melanoma and other solid tumors in adults.
Topics: Clinical Trials as Topic; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluatio | 1975 |
32 other studies available for lomustine and Benign Neoplasms
| Article | Year |
|---|---|
Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
Topics: Animals; Antineoplastic Agents; Benzopyrans; Cell Survival; Drug Design; Drug Screening Assays, Anti | 2008 |
The lomustine crisis: awareness and impact of the 1500% price hike.
Topics: Antineoplastic Agents, Alkylating; Drug Costs; Drug Industry; Humans; Lomustine; Neoplasms | 2019 |
Bacterial Sepsis Increases Survival in Metastatic Melanoma: Chlamydophila Pneumoniae Induces Macrophage Polarization and Tumor Regression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlamydophila Infections; Chlamy | 2016 |
CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
Topics: Anemia; Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Female; Gastrointestinal Dis | 2011 |
Low apparent risk of CCNU (lomustine)-associated clinical hepatotoxicity in cats.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents, Alkylating; Cat Diseases; Cats; Chemical and D | 2012 |
[Chemotherapy of malignant solid tumors].
Topics: Bleomycin; Breast Neoplasms; Bronchial Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Kidney Neo | 1980 |
Radiosensitizers: a conference preview.
Topics: Animals; Aziridines; Buthionine Sulfoximine; Carmustine; Combined Modality Therapy; Drug Synergism; | 1984 |
Modern problems of clinical chemotherapy of malignant tumours.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Carubicin; Dacarbazine; Dactinomycin; Drug Therapy, Co | 1980 |
Megadose chemotherapy with bone marrow rescue.
Topics: Animals; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma | 1984 |
[10 years' use of ftorafur in tumor chemotherapy at the Robert Rössle Institute. A retrospective analysis from the clinical-toxologic point of view].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Adm | 1984 |
Preclinical and clinical studies on chlorozotocin, a new nitrosourea with decreased bone marrow toxicity.
Topics: Animals; Bone Marrow; Carmustine; Drug Evaluation; Drug Evaluation, Preclinical; Female; Humans; Leu | 1980 |
A phase I study of the combination of benznidazole and CCNU in man.
Topics: Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Humans; Lomustine; Neoplasms; Nitroimida | 1984 |
[Secondary malignant tumors following treatment of Hodgkin's disease].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1984 |
In vitro cytotoxic drug sensitivity testing of human tumour xenografts grown as multicellular tumour spheroids.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Aggregation; Cell Division; Cell Line; Cispla | 1982 |
High dose chemotherapy and autologous bone marrow transplantation in acute leukemias, malignant lymphomas and solid tumors. A study of 23 patients.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Drug Therapy, Combinat | 1981 |
Sister chromatid exchange in human populations: the effect of smoking, drug treatment, and occupational exposure.
Topics: Crossing Over, Genetic; DNA Repair; Environmental Exposure; Humans; Lomustine; Neoplasms; Nitrosoure | 1982 |
Biodistribution of 14C-lomustine in an animal tumor model.
Topics: Animals; Antineoplastic Agents; Carbon Radioisotopes; Disease Models, Animal; Kidney; Lomustine; Neo | 1980 |
CCNU and bleomycin in the treatment of cancer: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Bleomycin; Bone Marrow Cells; Carcinoma, Squamous Cell; Dose-Response Relationship, | 1975 |
[High dose combination chemotherapy with and without autologous bone marrow transplantation in patients with solid tumors and acute leukemias. Kinetics of recovery of peripheral bloods cells (author's transl)].
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; | 1978 |
Tuberculosis and response to cancer chemotherapy.
Topics: Humans; Lomustine; Neoplasms; Tuberculosis | 1979 |
The effect of combination chemotherapy on the reticuloendothelial system in man.
Topics: Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lomustine; Mac | 1978 |
Rationale of chemotherapeutic adjuvant treatment.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Admi | 1978 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Treatment of advanced malignancy with CCNU (NSC 79037): a phase II cooperative study with long-term follow up.
Topics: Humans; Leukopenia; Lomustine; Neoplasms; Nitrosourea Compounds; Thrombocytopenia | 1976 |
Clinical studies with nitrosoureas in various solid tumors.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Carmustine; Female; Genital Neoplasms, F | 1976 |
Combination chemotherapy for advanced solid tumors with methyl-ccnu and beta-2'-deoxythioguanosine.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Lomustine; Male; Middle Aged; Neoplasms; Nit | 1976 |
Nitrosoureas: important new drugs for the treatment of cancer.
Topics: Carmustine; Humans; Lomustine; Neoplasms; Nitrosourea Compounds | 1976 |
Modulation of human lymphocyte O6-alkylguanine-DNA alkyltransferase by streptozotocin in vivo.
Topics: Carmustine; Cisplatin; DNA Repair; DNA, Neoplasm; Drug Resistance; Humans; Lomustine; Lymphocytes; M | 1989 |
[Various doses cisplatin combined with multi-drug chemotherapy of malignant solid tumors].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1989 |
Effects of CCNU therapy on human chromosomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Humans; Lomust | 1988 |
Misonidazole-induced chemopotentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea toxicity in O6-methylguanine-DNA methyltransferase proficient (Mer+) and deficient (Mer-) cell lines.
Topics: Animals; Cell Line; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; | 1986 |
[Results of a pilot study of hyaluronidase as an adjunct to cytostatic therapy in malignant diseases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Tolerance; Female; Humans; Hyaluro | 1985 |